Serum potassium in dual renin-angiotensin-aldosterone system blockade

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 2, 2014, Pages 219-221

  Seliger, Stephen L ^a   Fried, Linda F ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETIC NEPHROPATHIES; DIURETICS; FEMALE; HUMANS; LISINOPRIL; LOSARTAN; MALE; POTASSIUM; RENIN-ANGIOTENSIN SYSTEM; SPIRONOLACTONE;

EID: 84893620709     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.12411213     Document Type: Editorial

References (23)

1. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
2. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD; The Collaborative Study Group: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. NEngl J Med 329: 1456-1462, 1993
3. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001
4. de Zeeuw D: Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment? Kidney Int Suppl 66: S2-S6, 2004
5. Tobe SW, DaiMO:Outcomes of antiproteinuric RAAS blockade: High-dose compared with dual therapy. Curr Hypertens Rep 11: 345-353, 2009
6. Ponda MP, Hostetter TH: Aldosterone antagonism in chronic kidney disease. Clin J Am Soc Nephrol 1: 668-677, 2006
7. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators: Aliskiren combined with losartan in type 2 diabetes and nephropathy. NEngl JMed 358: 2433-2446, 2008
8. ParvingHH, Brenner BM, McMurray JJ, de ZeeuwD, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators: Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367: 2204-2213, 2012
9. Schrier RW: Renal and Electrolyte Disorders, 4th Ed., Boston, Little, Brown and Company, 1992
10. Palmer BF: A physiologic-based approach to the evaluation of a patient with hyperkalemia. Am J Kidney Dis 56: 387-393, 2010
11. Palmer BF: Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 351: 585-592, 2004
12. Khosla N, Kalaitzidis R, Bakris GL: Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 30: 418-424, 2009
13. Amir O, Hassan Y, Sarriff A, Awaisu A, Abd Aziz N, Ismail O: Incidence of risk factors for developing hyperkalemia when using ACE inhibitors in cardiovascular diseases. Pharm World Sci 31: 387-393, 2009
14. Weir MR, Rolfe M: Potassium homeostasis and reninangiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol 5: 531-548, 2010
15. DeFronzo RA: Hyperkalemia and hyporeninemic hypoaldosteronism. Kidney Int 17: 118-134, 1980
16. van Buren PN, Adams-Huet B, Nguyen M, Molina C, Toto RD: Potassiumhandlingwith dual renin-angiotensin systeminhibition in diabetic nephropathy. Clin J Am Soc Nephrol 9: 295-301, 2014
17. Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD: Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 20: 2641-2650, 2009
18. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C; ONTARGET Investigators: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358: 1547-1559, 2008
19. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S; ONTARGET investigators: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 372: 547-553, 2008
20. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, DuckworthW, Leehey DJ, McCullough PA, O'Connor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S, Peduzzi P, Guarino P; VA NEPHRON-D Investigators: Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369: 1892-1903, 2013
21. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J; Randomized Aldactone Evaluation Study Investigators: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341: 709-717, 1999
22. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl JMed 345: 1667-1675, 2001
23. Juurlink DN, MamdaniMM, LeeDS, KoppA, Austin PC, Laupacis A, Redelmeier DA: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351: 543-551, 2004